All articles by
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO Royalties
Proceeds expected to be used for stock repurchases and additional royalty and milestone acquisitions
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95m
Neurogene focused on advancing Phase 1/2 trial for NGN-401, a differentiated clinical stage gene therapy to treat Rett syndrome using its EXACT technology; interim clinical data expected in 4Q24
GC Biopharma’s Alyglo secures FDA approval for primary humoral immunodeficiency
Manufactured from pooled human plasma from American donors, Alyglo is a liquid solution with 10% immunoglobulin G (100 mg/mL) for intravenous infusion
Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries
Most of these products have been developed by Biocon Biologics and are being manufactured at its world-class facilities in India and Malaysia
EMA’s CHMP recommends Takeda’s Hyqvia approval as maintenance therapy in CIDP patients
The recommendation will be considered by the European Commission in deciding whether to allow Hyqvia for CIDP to be marketed across the European Union
CymaBay files FDA NDA for Seladelpar to treat primary biliary cholangitis
CymaBay seeks approval for PBC management including pruritus in adults without cirrhosis or with compensated cirrhosis who are inadequate responders or intolerant to ursodeoxycholic acid
Illumina Announces Decision to Divest GRAIL
The divestiture will be executed through a third-party sale or capital markets transaction
Totus Medicines Announces Appointment of Nassim Usman as President & CEO and the Closing of a $66M Series B Funding
Proceeds from the Series B financing will be used to advance Totus’ clinical program, expand the pipeline, and evolve the platform
Google introduces MedLM generative AI models for healthcare industry
MedLM is now accessible to Google Cloud users in the US, with a designated general availability on the Vertex AI platform
Merck receives FDA approval for Welireg to treat adult RCC patients
The approval was based on the data from an open-label, randomised, active-controlled LITESPARK-005 clinical trial in which Welireg showed statistically significant and clinically meaningful results